Centiva Capital, LP United Therapeutics Corp Transaction History

Centiva Capital, LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$228.26 - $319.04 $606,258 - $847,370	2,656 New	2,656 $846,000
Q4 2023 Feb 14, 2024	SELL	$214.88 - $256.94 $38,893 - $46,506	-181 Reduced 14.48%	1,069 $235,000
Q3 2023 Nov 14, 2023	BUY	$211.82 - $248.24 $264,775 - $310,300	1,250 New	1,250 $282,000
Q4 2021 Feb 14, 2022	SELL	$184.32 - $216.08 $322,191 - $377,707	-1,748 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$179.86 - $214.88 $193,349 - $230,996	-1,075 Reduced 38.08%	1,748 $320,000
Q2 2021 Aug 16, 2021	BUY	$170.47 - $211.93 $275,479 - $342,478	1,616 Added 133.89%	2,823 $506,000
Q1 2021 May 17, 2021	BUY	$153.94 - $174.85 $185,805 - $211,043	1,207 New	1,207 $202,000
Q1 2020 May 15, 2020	SELL	$79.39 - $115.35 $280,246 - $407,185	-3,530 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$78.31 - $95.34 $276,434 - $336,550	3,530 New	3,530 $311,000

668

42.8M

194K

295K

Ticker UTHR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,516,300
Market Cap $16.6B
Description
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...

Get notified when there are updates to the investment portfolio of Centiva Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Centiva Capital, LP with notifications on news.